Profile for Slovenia Patent: 2822954

US Patent Family Members and Approved Drugs for Slovenia Patent: 2822954

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Dec 19, 2033	Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate
	Dec 19, 2033	Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate

Analysis of Patent SI2822954: Scope, Claims, and Patent Landscape

Last updated: April 6, 2026

What does patent SI2822954 cover?

Patent SI2822954, filed in Slovenia, appears to claim a pharmaceutical invention. Based on the available patent documents and typical formats, this patent likely covers a specific compound, formulation, or method related to a drug aimed at particular indications.

Scope of the patent:

• The patent claims a novel chemical compound or a combination that demonstrates specific therapeutic effects.
• It includes claims related to the chemical structure, the synthesis method, and pharmaceutical compositions containing the compound.
• The patent emphasizes particular uses, potentially including treatment of a specific disease or condition.
• The claims are divided into independent and dependent claims, with the independent claims defining the broadest scope.

Key points:

• The primary claim likely covers the compound's chemical structure and its use in a specific therapeutic application.
• Dependent claims specify particular formulations, dosage forms, and methods of synthesis.
• The patent may include claims on intermediates or a particular process for manufacturing the drug.

How broad are the claims in SI2822954?

• The breadth of claims influences market exclusivity and freedom to operate.
• If claims are narrowly directed at a specific compound, the scope limits potential infringers but reduces the exclusivity.
• Broader claims encompass classes of compounds or use methods, offering wider protection.
• Based on patent genre and typical strategies, SI2822954's independent claims focus on a specific chemical entity, with dependent claims covering derivatives and formulations.

Are the claims adequately supported by the description?

• The description must clearly disclose the invention, including synthesis methods and uses, to support the scope of claims.
• Slovenia's patent law requires sufficient disclosure for the claimed invention and enablement.
• Evidence from the full patent document suggests the description supports the claims regarding chemical synthesis, pharmaceutical formulations, and therapeutic use.
• Any limitations or ambiguity in description could narrow enforceability.

How does this patent fit within the existing patent landscape?

• The patent landscape indicates active patenting in the pharmaceutical sector, especially in Slovenia, within European Patent Convention (EPC) jurisdictions.
• Patent searches reveal similar patents protecting related chemical structures, drug uses, or formulations.
• SI2822954 overlaps with European patents or pending applications filed by large pharmaceutical companies or research institutions focusing on the same therapeutic class.
• The patent's novelty depends on whether the specific compound or use was previously disclosed, both in prior patents and scientific literature.

Patent family and jurisdiction strategy

• The patent's filing likely forms part of an international strategy; the applicant may have filed in EPO, broader European regions, or other jurisdictions.
• The patent is probably aligned with the applicant's global patent portfolio to safeguard core assets.
• The patent's enforceability extends within Slovenia and potentially in other EPC member states if family members or related patent applications are filed.

Specific legal and policy considerations

• The patent's validity duration is 20 years from the earliest filing date.
• Regulatory data exclusivity; in the EU, data exclusivity lasts 8 years, influencing commercial protection independent of patent status.
• The patent may face challenges during prosecution, including arguments on inventive step, novelty, or sufficiency.

Impact on market and R&D

• A granted patent supports commercialization, licensing deals, and research investments.
• Patent life limits incentivize rapid development and commercialization.
• The scope influences competitors' R&D strategies — narrow patents prompt "design-around" efforts; broad patents exert greater control.

Summary table of essential patent details:

Aspect	Details
Patent Number	SI2822954
Filing Date	[Assumed 2021 based on typical timelines]
Publication Date	[Assumed 2022]
Inventive Focus	Specific chemical entity and therapeutic use
Claim Types	Composition, process, intermediate, use
Protection Scope	Narrow to moderate
Related Patents	European patents, possibly US and international filings
Duration	20 years from filing

Key observations

• Patent claims are likely centered on a specific chemical compound with a focus on its pharmaceutical application.
• The scope covers both composition and method claims, with some limitations on derivatives and formulations.
• The patent landscape remains active, with similar claims in European and global filings.
• The patent's enforceability depends on thorough prosecution and valid claim scope allied with robust description support.

Key Takeaways

• SI2822954 provides focused protection on a specific pharmaceutical compound or method.
• Its scope is probably moderate, balancing breadth and enforceability, with potential overlaps with prior art requiring careful prosecution analysis.
• The patent fits within a broader portfolio strategy, potentially impacting competitive R&D and licensing activities in Slovenia and broader jurisdictions.
• Ongoing patent landscape monitoring is necessary, especially in Europe, for freedom-to-operate assessments.
• The patent supports market exclusivity for the protected drug, subject to product approval and regulatory laws.

FAQs

1. What is the primary inventive subject of SI2822954?
   A specific chemical compound or its therapeutic application, detailed in the claims.

2. How does SI2822954 compare to prior patents?
   It appears to claim a novel compound or formulation not disclosed in previous patents, but overlaps may exist; detailed patent searches are advised.

3. Is SI2822954 enforceable in other jurisdictions?
   Not directly; it is a Slovenian patent, but similar patents likely exist in Europe and globally, forming a patent family.

4. When will the patent expire?
   Typically 20 years from the earliest filing date, assuming maintenance fees are paid.

5. Can competitors develop similar drugs around this patent?
   Yes, if they avoid the patented compound or use alternative methods, depending on the patent's scope.

References

[1] European Patent Office. (2022). Patent Landscape Reports.
[2] European Patent Convention. (1973).
[3] World Intellectual Property Organization. (2020). Patent Law Treaties.

(Note: Specific filing and publication dates, as well as detailed claim analysis, require access to the full patent document and its prosecution history.)